The role of metabolic and haemodynamic factors in podocyte injury in diabetes

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 3, 2011, Pages 207-215

  Stieger, Nicole ^a   Worthmann, Kirstin ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Apoptosis; Glucose; Nephropathy; Podocytes; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKINE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 8; OSTEOGENIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; BLOOD PRESSURE; CELL DAMAGE; CELL DEDIFFERENTIATION; DIABETIC NEPHROPATHY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE TRANSPORT; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY TUBULE PRESSURE; MECHANICAL STRESS; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PULSE PRESSURE; REVIEW; SHEAR STRESS;

ACTINS; APOPTOSIS; CHEMOKINES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOKINES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; PODOCYTES; STRESS, MECHANICAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 79952180728     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1164     Document Type: Review

References (109)

1. Atkins RC, Zimmet P. Diabetic kidney disease: act now or pay later. Kidney Int 2010; 77(5): 375-377.
2. Freedman BI, Hicks PJ, Bostrom MA, et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 2009; 24(11): 3366-3371.
3. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26(2): 163-175.
4. Love-Gregory LD, Wasson J, Ma J, et al. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 alpha gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an ashkenazi jewish population. Diabetes 2004; 53(4): 1134-1140.
5. Weedon MN, Owen KR, Shields B, et al. Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes 2004; 53(11): 3002-3006.
6. Craig DW, Millis MP, DiStefano JK. Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to Type 1 diabetes. Diabet Med 2009; 26(11): 1090-1098.
7. Thameem F, Puppala S, He X, et al. Evaluation of gremlin 1 (GREM1) as a candidate susceptibility gene for albuminuria-related traits in Mexican Americans with type 2 diabetes mellitus. Metabolism 2009; 58(10): 1496-1502.
8. McDonough CW, Hicks PJ, Lu L, et al. The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. Hum Genet 2009; 126(2): 265-275.
9. Petermann AT, Krofft R, Blonski M, et al. Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003; 64(4): 1222-1231.
10. Vogelmann SU, Nelson WJ, Myers BD, et al. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285(1): F40-F48.
11. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108(6): 807-816.
12. Huber TB, Hartleben B, Kim J, et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 2003; 23(14): 4917-4928.
13. Kim YH, Goyal M, Kurnit D, et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60(3): 957-968.
14. Steffes MW, Schmidt D, McCrery R, et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59(6): 2104-2113.
15. White KE, Bilous RW, Marshall SM, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria 25. Diabetes 2002; 51(10): 3083-3089.
16. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99(2): 342-348.
17. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42(11): 1341-1344.
18. Dalla VM, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52(4): 1031-1035.
19. Susztak K, Raff AC, Schiffer M, et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55(1): 225-233.
20. Coimbra TM, Janssen U, Grone HJ, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57(1): 167-182.
21. Menini S, Iacobini C, Oddi G, et al. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 2007; 50(12): 2591-2599.
22. Siu B, Saha J, Smoyer WE, et al. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. 2006; 7: 6.
23. Benigni A, Gagliardini E, Tomasoni S, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65(6): 2193-2200.
24. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52(4): 1023-1030.
25. Menne J, Meier M, Park JK, et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int 2006; 70(8): 1456-1462.
26. Yuan H, Takeuchi E, Salant DJ. Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton. Am J Physiol Renal Physiol 2002; 282(4): F585-F591.
27. Coward RJ, Welsh GI, Koziell A, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007; 56(4): 1127-1135.
28. Tossidou I, Starker G, Kruger J, et al. PKC-alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem 2009; 24(5-6): 627-634.
29. Lewko B, Bryl E, Witkowski JM, et al. Characterization of glucose uptake by cultured rat podocytes. Kidney Blood Press Res 2005; 28(1): 1-7.
30. Pozzi A, Jarad G, Moeckel GW, et al. Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol 2008; 316(2): 288-301.
31. Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 1997; 40(1): 15-22.
32. Chen HC, Chen CA, Guh JY, et al. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 2000; 67(19): 2345-2353.
33. Chen J, Gui D, Chen Y, et al. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition. Biochem Pharmacol 2008; 76(6): 796-804.
34. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108(11): 1583-1587.
35. Dessapt C, Baradez MO, Hayward A, et al. Mechanical forces and TGF{beta}1 reduce podocyte adhesion through {alpha}3{beta}1 integrin downregulation. Nephrol Dial Transplant 2009; 24(9): 2645-2655.
36. Han SY, Kang YS, Jee YH, et al. High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res 2006; 323(2): 321-332.
37. Attwell S, Roskelley C, Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000; 19(33): 3811-3815.
38. Kang YS, Li Y, Dai C, et al. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 2010; 78(4): 363-373.
39. Dandapani SV, Sugimoto H, Matthews BD, et al. Alpha-actinin-4 is required for normal podocyte adhesion. J Biol Chem 2007; 282(1): 467-477.
40. Ha TS. High glucose and advanced glycosylated end-products affect the expression of alpha-actinin-4 in glomerular epithelial cells. Nephrology (Carlton) 2006; 11(5): 435-441.
41. Schordan S, Schordan E, Endlich N, et al. Alterations of the podocyte proteome in response to high glucose concentrations. Proteomics 2009; 9(19): 4519-4528.
42. Vallon V, Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens 2010; 19(5): 425-431.
43. Schiffer M, Susztak K, Ranalletta M, et al. Localization of the GLUT8 glucose transporter in murine kidney and regulation in vivo in nondiabetic and diabetic conditions. Am J Physiol Renal Physiol 2005; 289(1): F186-F193.
44. Csibi A, Communi D, Muller N, et al. Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms. PLoS One 2010; 5(4): e10070.
45. Lennon R, Welsh GI, Singh A, et al. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 2009; 52(9): 1944-1952.
46. Brosius FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol 2005; 20(4): 447-451.
47. Heilig CW, Liu Y, England RL, et al. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 1997; 46(6): 1030-1039.
48. Wang Y, Heilig K, Saunders T, et al. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 2010; 299(1): F99-F111.
49. Zhang H, Schin M, Saha J, et al. Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2010; 299(1): F91-F98.
50. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 2006; 8(9-10): 1597-1607.
51. Gorin Y, Block K, Hernandez J, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280(47): 39616-39626.
52. Oba S, Hino M, Fujita T. Adrenomedullin protects against oxidative stress-induced podocyte injury as an endogenous antioxidant. Nephrol Dial Transplant 2008; 23(2): 510-517.
53. Wang Z, Wei X, Zhang Y, et al. NADPH oxidase-derived ROS contributes to upregulation of TRPC6 expression in puromycin aminonucleoside-induced podocyte injury. Cell Physiol Biochem 2009; 24(5-6): 619-626.
54. Eid AA, Gorin Y, Fagg BM, et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009; 58(5): 1201-1211.
55. Pieper AA, Verma A, Zhang J, et al. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999; 20(4): 171-181.
56. Szabo C, Biser A, Benko R, et al. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 2006; 55(11): 3004-3012.
57. Wolf G, Schanze A, Stahl RA, et al. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int 2005; 68(4): 1583-1589.
58. Yoo TH, Li JJ, Kim JJ, et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71(10): 1019-1027.
59. Jia J, Ding G, Zhu J, et al. Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008; 28(3): 500-507.
60. Godin CM, Ferguson SS. The angiotensin II type 1 receptor induces membrane blebbing by coupling to Rho A, Rho kinase, and myosin light chain kinase. Mol Pharmacol 2010; 77(6): 903-911.
61. Kolavennu V, Zeng L, Peng H, et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57(3): 714-723.
62. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009; 106(6): 1971-1976.
63. Schneider A, Ad N, Izhar U, et al. Protection of myocardium by cyclosporin A and insulin: in vitro simulated ischemia study in human myocardium. Ann Thorac Surg 2003; 76(4): 1240-1245.
64. Zeng QY, Zhang CM, Qian XH. Protective effects of continue insulin infusion on liver mitochondrion in the early stage of septic rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009; 25(6): 525-528.
65. Mogensen CE, Christensen NJ, Gundersen HJ. The acute effect of insulin on heart rate, blood pressure, plasma noradrenaline and urinary albumin excretion. The role of changes in blood glucose. Diabetologia 1980; 18(6): 453-457.
66. Jauregui A, Mintz DH, Mundel P, et al. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009; 18(6): 539-545.
67. Coward RJ, Welsh GI, Yang J, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54(11): 3095-3102.
68. Kanjanabuch T, Ma LJ, Chen J, et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71(12): 1232-1239.
69. Yang HC, Ma LJ, Ma J, et al. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69(10): 1756-1764.
70. Miyazaki Y, Cersosimo E, Triplitt C, et al. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007; 72(11): 1367-1373.
71. Kim MK, Ko SH, Baek KH, et al. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 2009; 24(3): 227-232.
72. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54(7): 2206-2211.
73. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118(5): 1645-1656.
74. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8(11): 1288-1295.
75. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277(1Pt1): E1-E10.
76. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428(6982): 569-574.
77. Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant 2009; 24(11): 3288-3296.
78. Suganami T, Mukoyama M, Mori K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J 2005; 19(1): 127-129.
79. Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 2010; 21(10): 589-598.
80. Tejada T, Catanuto P, Ijaz A, et al. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 2008; 73(12): 1385-1393.
81. Hyvonen ME, Saurus P, Wasik A, et al. Lipid phosphatase SHIP2 downregulates insulin signalling in podocytes. Mol Cell Endocrinol 2010; 328(1-2): 70-79.
82. Endlich N, Kress KR, Reiser J, et al. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001; 12(3): 413-422.
83. Friedrich C, Endlich N, Kriz W, et al. Podocytes are sensitive to fluid shear stress in vitro. Am J Physiol Renal Physiol 2006; 291(4): F856-F865.
84. Petermann AT, Hiromura K, Blonski M, et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002; 61(1): 40-50.
85. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162(4): 1123-1137.
86. Chuang PY, Yu Q, Fang W, et al. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int 2007; 72(8): 965-976.
87. Ruster C, Bondeva T, Franke S, et al. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008; 23(7): 2179-2191.
88. Puthalakath H, Huang DC, O'Reilly LA, et al. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3(3): 287-296.
89. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13(10): 2600-2610.
90. Wu DT, Bitzer M, Ju W, et al. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005; 16(11): 3211-3221.
91. Peters I, Tossidou I, Achenbach J, et al. IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol 2006; 17(6): 1644-1656.
92. Mueller-Deile J, Worthmann K, Saleem MA, et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009; 297(6): F1656-F1667.
93. Schiffer M, Mundel P, Shaw AS, et al. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004; 279(35): 37004-37012.
94. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14(3): 290-298.
95. Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002; 168(12): 6244-6252.
96. Niemir ZI, Stein H, Dworacki G, et al. Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int 1997; 52(2): 393-403.
97. Hino M, Nagase M, Kaname S, et al. Expression and regulation of adrenomedullin in renal glomerular podocytes. Biochem Biophys Res Commun 2005; 330(1): 178-185.
98. Sayyed SG, Hagele H, Kulkarni OP, et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009; 52(11): 2445-2454.
99. Tarabra E, Giunti S, Barutta F, et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009; 58(9): 2109-2118.
100. Sanchez-Nino MD, Sanz AB, Ihalmo P, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 2009; 20(2): 353-362.
101. Lorz C, Benito-Martin A, Boucherot A, et al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008; 19(5): 904-914.
102. De Petris L, Hruska KA, Chiechio S, et al. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007; 22(12): 3442-3450.
103. Turk T, Leeuwis JW, Gray J, et al. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 2009; 57(7): 623-631.
104. Wang S, de Caestecker M, Kopp J, et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17(9): 2504-2512.
105. Mitu GM, Wang S, Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007; 293(5): F1641-F1648.
106. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82(3): 175-181.
107. Yamaguchi Y, Iwano M, Suzuki D, et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54(4): 653-664.
108. Appel D, Kershaw DB, Smeets B, et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20(2): 333-343.
109. Fioretto P, Sutherland DE, Najafian B, et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69(5): 907-912.